Shanghai Henlius Biotech's (HKG:2696) new drug application for a new indication of Hansizhuang was approved by China's National Medical Products Administration, according to a Tuesday Hong Kong bourse filing.
The approval is for use of the drug in combination with Oxaliplatin and S-1 for the neoadjuvant
treatment of resectable gastric cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments